Greffex Inc. Signs Manufacturing Contract with FUJIFILM Diosynth Biotechnologies to Produce Vaccines

Greffex, a leading genetic engineering company, with the world’s first universal vaccine platform delivered through the use of proprietary clean viral vectors, recently announced a key manufacturing agreement with FUJIFILM Diosynth Biotechnologies to produce its vaccine in the United States. Greffex’s platform is the world’s most successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including vaccines, immune suppression and gene therapy.